Literature DB >> 24395189

Serum and plasma neutrophil gelatinase associated lipocalin (NGAL) levels are not equivalent in patients admitted to intensive care.

Theis Skovsgaard Itenov1, Kristian Bangert, Per Hjort Christensen, Jens-Ulrik Jensen, Morten Heiberg Bestle.   

Abstract

BACKGROUND: Neutrophil gelatinase associated lipocalin (NGAL) is proposed as a biomarker of acute kidney injury (AKI). NGAL has been studied in a range of body fluids including serum and EDTA plasma. The aim of the present study was to establish relationship between serum NGAL concentrations and EDTA plasma NGAL concentrations in patients admitted to intensive care units (ICUs) and whether these determinations are directly comparable in this setting.
METHODS: NGAL was measured in 40 paired samples of serum and EDTA plasma from 25 patients admitted to intensive care with a commercial particle-enhanced turbidimetric immunoassay (The NGAL Test™, BioPorto Diagnostics A/S, Gentofte, Denmark) on a Roche Hitachi 917 (Roche-Hitachi, Inc., Tokyo, Japan) analyzer.
RESULTS: Serum NGAL concentrations ranged from 26.8 to 1,808 ng/ml (median 281 ng/ml, interquartile range (IQR) 453 ng/ml). EDTA plasma NGAL concentrations ranged from 25.7 to 1,752 ng/ml (median 225 ng/ml, IQR 352 ng/ml). The difference in NGAL concentrations in paired serum and EDTA plasma samples (serum- plasma) ranged from -13.8 to 321 ng/ml (median 79 ng/ml, IQR 116 ng/ml; difference from zero, P < 0.0001, Wilcoxon's signed rank test). Although serum and EDTA plasma values were correlated (Spearman's r = 0.95, P < 0.0001), Deming regression analysis showed a slope of 1.1 that was not significantly different from unity (95% confidence interval (CI) 1.0-1.1) and a highly significant intercept of 67.9 ng/ml with a wide confidence interval (95% CI 29.8-106).
CONCLUSION: NGAL concentration values measured in serum and EDTA plasma cannot be directly compared and should not be used as equivalents in studies of patients admitted to intensive care.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  acute kidney injury; biomarkers; critical illness; neutrophil gelatinase-associated lipocalin (NGAL); plasma; serum

Mesh:

Substances:

Year:  2014        PMID: 24395189      PMCID: PMC6807606          DOI: 10.1002/jcla.21662

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  24 in total

Review 1.  Measuring agreement in method comparison studies.

Authors:  J M Bland; D G Altman
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

2.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

3.  Prognostic value of serum neutrophil gelatinase-associated lipocalin in metastatic and nonmetastatic colorectal cancer.

Authors:  Josep Martí; Josep Fuster; Anna M Solà; Georgina Hotter; Rafael Molina; Amalia Pelegrina; Joana Ferrer; Ramon Deulofeu; Constantino Fondevila; Juan Carlos García-Valdecasas
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

4.  Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils.

Authors:  L Kjeldsen; D F Bainton; H Sengeløv; N Borregaard
Journal:  Blood       Date:  1994-02-01       Impact factor: 22.113

5.  The development of an assay for human neutrophil lipocalin (HNL)--to be used as a specific marker of neutrophil activity in vivo and vitro.

Authors:  S Y Xu; C G Petersson; M Carlson; P Venge
Journal:  J Immunol Methods       Date:  1994-05-16       Impact factor: 2.303

6.  Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury.

Authors:  Philipp Kümpers; Carsten Hafer; Alexander Lukasz; Ralf Lichtinghagen; Korbinian Brand; Danilo Fliser; Robert Faulhaber-Walter; Jan T Kielstein
Journal:  Crit Care       Date:  2010-02-01       Impact factor: 9.097

Review 7.  Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences.

Authors:  Aldo Clerico; Claudio Galli; Antonio Fortunato; Claudio Ronco
Journal:  Clin Chem Lab Med       Date:  2012-02-15       Impact factor: 3.694

Review 8.  Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis.

Authors:  Michael Haase; Rinaldo Bellomo; Prasad Devarajan; Peter Schlattmann; Anja Haase-Fielitz
Journal:  Am J Kidney Dis       Date:  2009-10-21       Impact factor: 8.860

9.  Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial.

Authors:  Jens-Ulrik Stæhr Jensen; Lars Hein; Bettina Lundgren; Morten Heiberg Bestle; Thomas Mohr; Mads Holmen Andersen; Klaus Julius Thornberg; Jesper Løken; Morten Steensen; Zoë Fox; Hamid Tousi; Peter Søe-Jensen; Anne Øberg Lauritsen; Ditte Gry Strange; Nanna Reiter; Katrin Thormar; Paul Christian Fjeldborg; Kim Michael Larsen; Niels-Erik Drenck; Maria Egede Johansen; Lene Ryom Nielsen; Christian Ostergaard; Jesper Kjær; Jesper Grarup; Jens D Lundgren
Journal:  BMJ Open       Date:  2012-03-11       Impact factor: 2.692

10.  Comparison of Serum and Urine Neutrophil Gelatinase-Associated Lipocalin (NGAL) With Serum Creatinine in Prediction of Kidney Suitability for Transplantation.

Authors:  Mitra Mahdavi-Mazdeh; Alireza Abdollahi; Behnaz Nozary Heshmati; Zahra Sobhani
Journal:  Nephrourol Mon       Date:  2012-12-15
View more
  6 in total

Review 1.  Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.

Authors:  Giovanni Lombardi; Mosè Barbaro; Massimo Locatelli; Giuseppe Banfi
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

2.  Plasma neutrophil gelatinase-associated lipocalin predicts acute pyelonephritis in children with urinary tract infections.

Authors:  Ji Hyun Sim; Hyung Eun Yim; Byung Min Choi; Jee Hyun Lee; Kee Hwan Yoo
Journal:  Pediatr Res       Date:  2015-03-19       Impact factor: 3.756

3.  Diagnostic Utility of Serum Neutrophil Gelatinase-Associated Lipocalin in Polytraumatized Patients Suffering Acute Kidney Injury: A Prospective Study.

Authors:  Lukas Leopold Negrin; Reinhard Hahn; Thomas Heinz; Stefan Hajdu
Journal:  Biomed Res Int       Date:  2018-11-06       Impact factor: 3.411

4.  Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals.

Authors:  Alessio Strazzulla; Giuseppe Coppolino; Giorgio Settimo Barreca; Innocenza Gentile; Laura Rivoli; Maria Concetta Postorino; Maria Mazzitelli; Giuseppe Greco; Chiara Costa; Vincenzo Pisani; Nadia Marascio; Mariadelina Simeoni; Alfredo Focà; Giorgio Fuiano; Daniela Foti; Elio Gulletta; Carlo Torti
Journal:  Clin Mol Hepatol       Date:  2018-04-24

5.  Plasma Lipocalin 2 in Alzheimer's disease: potential utility in the differential diagnosis and relationship with other biomarkers.

Authors:  Peter Hermann; Anna Villar-Piqué; Inga Zerr; Franc Llorens; Matthias Schmitz; Christian Schmidt; Daniela Varges; Stefan Goebel; Timothy Bunck; Hanna Lindemann; Carla Bogner; Isabel Santana; Inês Baldeiras; Joachim Riggert
Journal:  Alzheimers Res Ther       Date:  2022-01-13       Impact factor: 6.982

6.  Predictive value of cystatin C and neutrophil gelatinase-associated lipocalin in contrast-induced nephropathy: A meta-analysis.

Authors:  Yi He; Yunzhen Deng; Kaiting Zhuang; Siyao Li; Jing Xi; Junxiang Chen
Journal:  PLoS One       Date:  2020-04-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.